Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: An analysis from the clopidogrel for the reduction of events during observation trial

Circulation: Cardiovascular Interventions

Volumn 2, Issue 6, 2009, Pages 503-512

  Dosh, Kristofer ^a   Berger, Peter B ^b   Marso, Steven ^c   Lente, Fredrick Van ^d   Brennan, Danielle M ^d   Charnigo, Richard ^e   Topol, Eric J ^f   Steinhubl, Steven ^b,g  

^a UNIVERSITY OF KENTUCKY   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^g Medicines Company   (Switzerland)

Author keywords

Blood platelets; Catheterization; Coronary disease; Inflammation; Pharmaceutical preparations

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UP-REGULATION;

EID: 77953673449     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.109.879312     Document Type: Article

References (37)

1. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54: 24-38.
2. Elesber AA, Conover CA, Denktas AE, Lennon RJ, Holmes DR Jr, Overgaard MT, Christiansen M, Oxvig C, Lerman LO, Lerman A. Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina. Eur Heart J. 2006;27:1678 -1684.
3. Ferrante G, Niccoli G, Biasucci LM, Liuzzo G, Burzotta F, Galiuto L, Trani C, Rebuzzi AG, Crea F. Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med. 2008; 9:156 -165.
4. Huang PH, Lu TM, Wu TC, Lin FY, Chen YH, Chen JW, Lin SJ. Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease. Coron Artery Dis. 2008;19:187-193.
5. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N,Baldazzi F, Silenzi S, Bacchi-Reggiani ML, Guastaroba P, Grilli R,Branzi A. Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur Heart J. 2008;29:1241-1249.
6. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A,Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
7. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639.
8. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
9. Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-980
10. Ridker P, Rifai N, Clearfield M, Downs J, Weis S, Miles J, Gotto A.Measurement of C-reactive protein for the targeting of statin therapy inthe primary prevention of acute coronary events. N Engl J Med. 2001;344:1959 -1965.
11. Ridker P, Cannon C, Morrow D, Rifai N, Rose L, McCabe C, Pfeffer M, Braunwald E. C-reactive protein levels and outcomes after statin therapy.N Engl J Med. 2005;352:20 -28.
12. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29 -38.
13. Chew DP, Bhatt DL, Robbins MA, Mukherjee D, Roffi M, Schneider JP, Topol EJ, Ellis SG. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001;88:672- 674.
14. Vivekananthan DP, Bhatt DL, Chew DP, Zidar FJ, Chan AW, Moliterno DJ, Ellis SG, Topol EJ. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.Am J Cardiol. 2004;94:358-360.
15. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS. Pregnancy associated plasma protein A as a marker of acute coronary syndromes.N Engl J Med. 2001;345:1022-1029.
16. Lund J, Qin QP, Ilva T, Pettersson K, Voipio-Pulkki LM, Porela P,Pulkki K. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation. 2003;108:1924 -1926.
17. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM. Pregnancy-associated plasma protein- A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol. 2005;45:229 -237.
18. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc. 2002;288:2411-2420.
19. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III,Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SCJr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation.2003;107:499 -511.
20. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
21. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155:687- 693.
22. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
23. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
24. Iijima R, Byrne RA, Ndrepepa G, Braun S, Mehilli J, Berger PB,Schomig A, Kastrati A. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with andwithout abciximab: pooled analysis of four ISAR trials. Heart. 2009;95:107-112.
25. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation.1999;100:230 -235.
26. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc. 2001;286:64 -70.
27. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191-1193.
28. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003;23:2131-2137.
29. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of plateletsin inflammation. J Thromb Haemost. 2003;1:1897-1905.
30. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation.1999;100:793-798.
31. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, HarderS. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther. 2003;73:232-241.
32. Vavuranakis M, Latsios G, Aggelis D, Bosinakou I, Karambelas I, Tousoulis D, Toutouzas K, Stefanadis C. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Ther. 2006;28:860-871.
33. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, Plow E, Topol EJ. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.Am J Cardiol. 2004;93:679-684. (Pubitemid 38338553)
34. Kreutz RP, Tantry US, Bliden KP, Gurbel PA. Inflammatory changes during the common cold' are associated with platelet activation and increased reactivity of platelets to agonists. Blood Coagul Fibrinolysis.2007;18:713-718.
35. Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin nonresponsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost. 2007;5:507-511.
36. Canavan B, Salem RO, Schurgin S, Koutkia P, Lipinska I, Laposata M, Grinspoon S. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab. 2005;90:5779 -5785.
37. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.